Anti–Epidermal Growth Factor Receptor Maintenance Therapy in Metastatic Colorectal Cancer—Another Piece to the Puzzle
JAMA Network Open · 18.09.2023 · 6 (9) · e2333488
DOI: 10.1001/jamanetworkopen.2023.33488 ↗Kurz gefasst
Kommentar in der Zeitschrift JAMA Network Open, online erschienen am 18.09.2023. Verfasst von Federica Morano und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. Hauptthemen laut MEDLINE: Colonic Neoplasms, Rectal Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 10 Literaturangaben.
Abstract (Originalsprache)
According to current guidelines, doublet chemotherapy plus an anti-epidermal growth factor receptor (EGFR) agent is the recommended upfront treatment option in patients with RAS or BRAF wild-type metastatic colorectal cancer (mCRC), specifically in left-sided tumors.1,2 Although these combinations have significantly improved overall survival (OS), up to approximately 3 years, the duration of first-line therapy is still a matter of debate.Disabling and cumulative adverse effects, especially oxaliplatin-related neuropathy, can worsen during prolonged treatment, severely affecting quality of life.The need to limit these toxic effects in patients with disease not amenable to local treatment after achieving maximum tumor response has led to the idea of intermittent or maintenance therapy.Several randomized clinical trials have investigated different therapeutic approaches, such as observation or deescalation of treatment intensity, instead of continuing induction therapy until disease progression.Data are more robust with bevacizumab used as the targeted agent in maintenance setting.A 2020 network meta-analysis 3 found no benefit from continuing bevacizumab-based induction therapy until progressive disease (PD), while a significant progression-free survival (PFS) benefit was documented with fluoropyrimidine (5-FU) and leucovorin (LV) plus bevacizumab as maintenance therapy vs observation.However, no significant trend for overall survival (OS) was observed in favor of maintenance therapy.3 Maintenance strategies with anti-EGFR agents have been long debated, especially due to their peculiar adverse events; while bevacizumab has a relatively manageable toxicity profile, skin rash or gastrointestinal toxic effects induced by EGFR inhibition may negatively impact quality of life and hinder a prolonged maintenance strategy.The TIME-PRODIGE-28 study by Boige et al 4 addressed the efficacy of maintenance therapy with single-agent cetuximab vs a treatment-free interval after a 4-month induction treatment with 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) and cetuximab in patients with RAS wild-type mCRC.In this phase 2 noncomparative trial, patients were randomized 1:1 to maintenance therapy with biweekly cetuximab or observation after achieving disease control with 8 cycles of induction therapy.After PD, reinduction with FOLFIRI and cetuximab was recommended and was followed by maintenance or observation according to the original randomization group.The primary end point was the progression-free rate at 6 months from randomization.The sample size calculation was based on a Fleming 1-step design, and cetuximab maintenance therapy was considered effective if more than 50% of patients (34 of 67 patients) were alive and without PD at 6 months after randomization.Among 214 included patients, 139 achieved disease control and were randomized to either maintenance therapy with biweekly cetuximab (67 patients) or observation (72 patients).At a median follow-up of 40.5 months, 26 patients (38.8%) receiving maintenance therapy and 4 patients (5.6%) in the observation control group were alive without PD at 6 months after randomization, not reaching the prespecified threshold in either group.Although not powered for comparison, results were disappointing, with a median PFS from randomization of 2.0 months vs 5.3 months in the observation vs maintenance group, and a median OS from randomization of 19.7 months vs 24.8 months, respectively.In terms of safety, the incidence of adverse effects was expectedly increased in the maintenance therapy group, particularly skin rash (11.9% of patients) and diarrhea (6% of patients).Interestingly, next-generation sequencing analysis on available tumor samples showed activating alterations in the mitogen-activated protein kinases pathway (Ն1 alteration in RAS, BRAF, MAP2K1, or RTK genes) in 28.6% of patients, with the expected +
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Zitieren
APA
Morano, F., & Pietrantonio, F. (2023). Anti–Epidermal Growth Factor Receptor Maintenance Therapy in Metastatic Colorectal Cancer—Another Piece to the Puzzle. JAMA Network Open, 6(9), e2333488. https://doi.org/10.1001/jamanetworkopen.2023.33488
Vancouver
Morano F, Pietrantonio F. Anti–Epidermal Growth Factor Receptor Maintenance Therapy in Metastatic Colorectal Cancer—Another Piece to the Puzzle. JAMA Network Open. 2023;6(9):e2333488. doi:10.1001/jamanetworkopen.2023.33488
BibTeX
@article{Morano2023,
author = {Morano, Federica and Pietrantonio, Filippo},
title = {Anti–Epidermal Growth Factor Receptor Maintenance Therapy in Metastatic Colorectal Cancer—Another Piece to the Puzzle},
journal = {JAMA Network Open},
year = {2023},
volume = {6},
number = {9},
pages = {e2333488},
doi = {10.1001/jamanetworkopen.2023.33488}
}
EUVIMED